Several multinationals in India continue to be sole sellers of certain cancer drugs even after product patents expire, with generic companies unwilling or unable to enter the market due to various barriers including manufacturing and regulatory. 27 March 2019
The share of domestic drugs in the public procurements in Russia has reached record figures for the last four years and currently continues to grow, according to recent statistics, published by the Russian Ministry of Health and statements of some local analysts in the field of pharmaceutics. 25 March 2019
Japanese pharma giant Takeda has officially announced the suspension of supplies of at least three branded generic drugs to the Russian market this year, reports The Pharma Letter’s local correspondent. 25 March 2019
Judging which companies are topping the oncology research charts in any given quarter or year can be highly subjective, but sometimes drugmakers present a series of new findings at once that make their activities hard to ignore. 22 March 2019
Paroxysmal Nocturnal Hemoglobinuria (PNH) hit the news at the end of 2018 when the US Food and Drug Administration approved Ultomiris (ravulizumab-cwvz; Alexion) as a treatment for this very rare blood condition. This is ground-breaking news for a condition that is known to affect only one to nine people per million worldwide. 21 March 2019
A piquant situation has emerged in India. The Indian government's generic medicine scheme is hurting the local pharmaceutical market, and is proving to be a major challenge for branded generic players. 20 March 2019
An Expert View looking at the key factors that will drive deal activity over the next year from Michael Jewell, partner, head of healthcare & life sciences at Cavendish Corporate Finance. 18 March 2019
The end of a drug’s exclusivity period can result in expensive patent litigation, and IP lawyer Kent Walker has identified an emerging trend that could present a solution for generic challengers seeking to enter the market. 18 March 2019
Russian‘s leading drugmaker Biocad has registered a biosimilar of Humira (adalimumab), the world’s best-selling drug, used for the treatment of rheumatoid arthritis and psoriasis, among other inflammatory conditions, according to the company. 15 March 2019
A new procedure for the suspension of the use and sales of drugs in the Russian market has been developed by the Russian Ministry of Health, which used the existing federal law “On the Circulation of Medicinal Products in Russia” during its design, according to an official spokesman of the Ministry, reports The Pharma Letter’s local correspondent. 15 March 2019
Even if the UK parliament votes against ‘no deal’ on Wednesday, in the wacky world of Brexit, this cliff-edge scenario is still possible – so Stevens & Bolton partner Charlotte Tillett and senior associate Paula Harris, consider the potential implications for pharma in an Expert View piece. 13 March 2019
Two tuberculosis survivors have opposed a patent application filed in India by Janssen Pharmaceutica, which they say could block generic versions of bedaquiline, a drug recommended for the treatment of multi drug resistant tuberculosis (MDR-TB), until 2027. 11 March 2019
Leading Russian pharmaceutical producers plan to significantly increase exports of their drugs to foreign markets during the next several years and to localize their production, according to recent statements by the companies, reports The Pharma Letter’s local correspondent. 8 March 2019
Research shows some 79% of the American public view the cost of prescription drugs as unreasonable, and lawmakers and regulators are increasingly convinced the industry charges too much for its products. 8 March 2019
The authorities of Moscow region has signed a second investment agreement with Russia’s leading drugmaker R-Pharm on the production of anticancer drugs within the territory of the Moscow region, according to press-service of the Moscow city government. 8 March 2019
In January of this year, the US Food and Drug Administration released updated draft guidance for industry entitled “Rare Diseases: Common Issues in Drug Development.” This replaces the previous version issued in 2015.1 7 March 2019
Even as more blood pressure drugs are being recalled in the USA after being found to contain trace amounts of a potentially cancer-causing ingredient, India’s drug controller is putting stringent quality control measures in place aiming to boost public confidence in generic medicines, reports The Pharma Letter’s India correspondent. 5 March 2019
In recent years, the pharmaceutical industry has seen tremendous changes in the way it is expected to deliver new drugs to market: being under increasing pressure to expedite the development of new therapies, to decrease clinical study duration, and to drive new treatments through their clinical phases as quickly, safely and cost-efficiently as possible. 5 March 2019
“Everyone in the ecosystem recognizes that there's going to a lot of innovations coming forward in the next years and those need to get to patients.” 3 March 2019
Aspirin may be over 100 years old, but OtiTopic believes the potential of the analgesic workhorse to provide innovative therapies is yet to be exhausted. 1 March 2019
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024